Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Eisai confirms 20% cut in US workforce

March 8, 2011 Manufacturing and Production, Research and Development, Sales and Marketing Aricept, Eisai, Halaven, US, donepezil, eribulin, pharma job cuts

Eisai’s planned job cuts will fall heaviest on its US operations, where 20% of the workforce will be let go …
News
Merck & Co workers protest job cuts

Merck says sale of Oss facility would be too expensive

March 8, 2011 Manufacturing and Production, Research and Development Holland, Merck & Co, Oss, Oss pharma research, Pantarhei Bioscience

The debate around the closure of Merck & Co’s R&D and manufacturing unit in Oss, the Netherlands, rumbles on, with …
News

Ethical practices – pharma’s obligation

March 8, 2011 Research and Development, Sales and Marketing ethics, industry relations, industry reputation

Pharmaceutical companies are not charities, and neither is any other business, by definition. Capitalism as a recognised system has been …
Feature
GlaxoSmithKline's London headquarters

GSK ends neuroscience research alliance

March 7, 2011 Research and Development GSK, GlaxoSmithKline, Targacept, neuronal nicotinic receptors, neuroscience research

GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. GSK forked out $45 million …
News

Government injects £775m into NHS translational research

March 7, 2011 Research and Development ABPI, Kent, NHS research, Pfizer research Kent, Sandwich, Science and Technology Select Committee, translational research

The government has pledged around £775 million for translational research, saying it will help modernise the health service and support …
News
Novo Nordisk's Victoza

Novo’s Victoza beats Bydureon in head-to-head trial

March 4, 2011 Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes

Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
News
Science minister David Willetts

Universities to ‘pick up pharma’s R&D mantle’ after Pfizer closure

March 3, 2011 Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee, UK research, UK science, job cuts

Science in the UK will have to focus on contractually-based research in the future as pharma’s R&D presence in the …
News
GlaxoSmithKline's London headquarters

GSK to reimburse tuition fees for UK trainees

March 3, 2011 Business Services, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment

GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012. Each year, GSK recruits between …
News
The RNA interference process

RNA interference – still the great white hope?

March 3, 2011 Manufacturing and Production, Research and Development RNA interference, rnai

The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …
Feature

UCB teams up with Harvard for CNS research

March 2, 2011 Research and Development CNS, Harvard, UCB, academia, academic research, immunology

UCB has signed a new research collaboration with Harvard University that will focus on central nervous system and immunology therapies. …
News
brecon_kay_ohagan

Boehringer’s Kay O’Hagan moves to Brecon

March 2, 2011 Manufacturing and Production, Research and Development Brecon, Kay O'Hagan, appointment, manufacturing and production, research and development

Kay O’Hagan has joined commercial packaging and clinical trials supply services company Brecon Pharmaceuticals as director of quality assurance and …
Appointment

GlaxoSmithKline seeks alliances with ‘academic superstars’

March 2, 2011 Research and Development GSK, GlaxoSmithKline, Pentraxin Therapeutics, academia, al Free and University College Medical School, universities

GlaxoSmithKline has unveiled a partnership with a ‘superstar academic’, as part of a new strategy which it believes will help …
News

Daiichi Sankyo gains rights to potential blockbuster cancer drug

March 2, 2011 Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine

Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
News
Bayer's Marijn Dekkers

Bayer goes for pharma growth

March 1, 2011 Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto

While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …
Feature

Pfizer drops 15 pipeline projects

March 1, 2011 Research and Development Lyrica, Pfizer, Pfizer R&D, Pfizer product pipeline, Pfizer research, inotuzumab, pregabalin

Pfizer has again slimmed down its product pipeline as the US giant looks to cut R&D spending and sharpen its …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026